Trial Profile
A Phase 1b and 2a Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX9486 as a Single Agent and in Combination With PLX3397 or Sunitinib (Sutent) in Patients With Advanced Solid Tumors and Patients With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumor (GIST) Who Have Been Previously Treated With Imatinib Mesylate/KIT-Directed Tyrosine Kinase Inhibitor (TKI) Therapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bezuclastinib (Primary) ; Pexidartinib (Primary) ; Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Cogent Biosciences; Plexxikon
- 18 Nov 2020 Final results from this study for PLX9486 + Sunitinib combination (n=18), presented in a Cogent Biosciences media release.
- 05 Oct 2020 According to an Unum Therapeutics media release, detailed results of this study will be presented as an oral presentation at the upcoming 2020 CTOS Annual Meeting.
- 24 Jul 2020 Status changed from active, no longer recruiting to completed.